Overtime post-HSCT, AML patients did not show significant differences in the surface expression of PD-1, CTLA-4, and TIM-3 within CMV-CTL or WT1-CTL (Figure 3A). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.